|
|
||||||||
B Activation1



* Vascular System Research Center and Department of Molecular and Cellular Biochemistry, and
Department of Orthopaethic Surgery, School of Medicine, Kangwon National University, Chunchon, Kangwon-do, Korea;
Department of Surgery, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213;
Department of Microbiology and Immunology, Wonkwang University School of Medicine, Iksan, Chonbuk, Korea;
¶ Department of Biology, College of Natural Science, Chunchon, Kangwon-do, Korea;
|| Department of Biochemistry, College of Science, Yonsei University, Seoul, Korea; and
# Drug Discovery, Research, and Development Center, LG Life Sciences, Taejon, Korea
Farnesylation of p21ras is an important step in the intracellular signaling pathway of growth factors, hormones, and immune stimulants. We synthesized a potent and selective farnesyltransferase inhibitor (LB42708) with IC50 values of 0.8 nM in vitro and 8 nM in cultured cells against p21ras farnesylation and examined the effects of this inhibitor in the settings of inflammation and arthritis. LB42708 suppressed NF-
B activation and iNOS promoter activity by suppressing the I-
B kinase activity and I-
B
degradation. The inhibitor suppressed the expression of inducible NO synthase, cyclooxygenase-2, TNF-
, and IL-1
and the production of NO and PGE2 in immune-activated macrophages and osteoblasts as well as LPS-administrated mice. Furthermore, in vivo administration of LB42708 significantly decreased the incidence and severity of arthritis as well as mRNA expression of inducible NO synthase, cyclooxygenase-2, TNF-
, and IL-1
in the paws of collagen-induced arthritic mice compared with controls. These observations indicate that the anti-inflammatory and antiarthritic effects of the farnesyltransferase inhibitor may be ascribed to the inhibition of I-
B kinase activity and subsequent suppression of NF-
B-dependent inflammatory gene expression through the suppression of p21ras farnesylation. Together, these findings reveal that the inhibitory effect of LB42708 on p21ras-dependent NF-
B activation may have potential therapeutic value for arthritis and other inflammatory diseases.
This article has been cited by other articles:
![]() |
R. Ahmad, J. Sylvester, M. Ahmad, and M. Zafarullah Adaptor Proteins and Ras Synergistically Regulate IL-1-Induced ADAMTS-4 Expression in Human Chondrocytes J. Immunol., April 15, 2009; 182(8): 5081 - 5087. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Prasanna, B. Saha, and D. Nandi Involvement of oxidative and nitrosative stress in modulation of gene expression and functional responses by IFN{gamma} Int. Immunol., July 2, 2007; (2007) dxm058v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Raponi, J.-L. Harousseau, J. E. Lancet, B. Lowenberg, R. Stone, Y. Zhang, W. Rackoff, Y. Wang, and D. Atkins Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia Clin. Cancer Res., April 1, 2007; 13(7): 2254 - 2260. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Byun, I.-K. Hong, E. Kim, Y.-J. Jin, D.-I. Jeoung, J.-H. Hahn, Y.-M. Kim, S. H. Park, and H. Lee A Splice Variant of CD99 Increases Motility and MMP-9 Expression of Human Breast Cancer Cells through the AKT-, ERK-, and JNK-dependent AP-1 Activation Signaling Pathways J. Biol. Chem., November 17, 2006; 281(46): 34833 - 34847. [Abstract] [Full Text] [PDF] |
||||
![]() |
I.-K. Hong, Y.-J. Jin, H.-J. Byun, D.-I. Jeoung, Y.-M. Kim, and H. Lee Homophilic Interactions of Tetraspanin CD151 Up-regulate Motility and Matrix Metalloproteinase-9 Expression of Human Melanoma Cells through Adhesion-dependent c-Jun Activation Signaling Pathways J. Biol. Chem., August 25, 2006; 281(34): 24279 - 24292. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xue, K.-T. A. Lai, J.-F. Huang, Y. Gu, L. Karlsson, and A. Fourie Anti-Inflammatory Activity in Vitro and in Vivo of the Protein Farnesyltransferase Inhibitor Tipifarnib J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 53 - 60. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |